All In Biotech

Drug Trial Radar · NCT06319274

Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure

Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 ng/kg/Min) in Mechanically Ventilated Patients With Infectious Pulmonary Endotheliopathy - a Multicenter Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Apr 15, 2024

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Pär JohanssonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 450 mechanically ventilated patients with infectious respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival.

Conditions

  • Acute Respiratory Failure
  • Endothelial Dysfunction
  • Pulmonary Infection

Interventions

  • IloprostDrug

    Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min

  • Isotonic salineDrug

    Continuously infusion for 72 hours at 3 ml/hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day mortalityTime frame: Day 28

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital

    Copenhagen, Denmark · Recruiting

  • Dept. of Intensive Care, Copenhagen University Hospital Herlev

    Herlev, Denmark · Recruiting

  • Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital

    Hillerød, Denmark · Recruiting

  • Dept. of Intensive care, Hvidovre Hospital

    Hvidovre, Denmark · Recruiting

  • Department of Anesthesia and Intensive Care Medicine, Zealand University Hospital

    Køge, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.